The city of Los Angeles, California, currently has 379 active clinical trials seeking participants for Cancer research studies.
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
Recruiting
This is an open-label, Phase 1b study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/07/2022
Locations: USC Norris Comp. Cancer Ctr Hospital, Los Angeles, California
Conditions: Gastric Cancer
LIFE Cancer Survivorship Database for Pediatric Cancer
Recruiting
The purpose of this study is to develop a mechanism for utilizing the comprehensive clinical database of childhood cancer survivors at Childrens Hospital Los Angeles (CHLA) for research purposes. Using clinical information obtained from follow-up visits of childhood cancer survivors, the database will focus on interventions to improve health status and health-related quality of life in childhood cancer survivors. This study allows for establishment and analyses of a research database for LIFE su... Read More
Gender:
All
Ages:
All
Trial Updated:
06/09/2022
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Pediatric Cancer
International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors
Recruiting
Partial nephrectomy (PN) is the standard treatment for localized renal masses and should be preferred in clinical T1 (<7 cm tumor diameter) renal tumors over radical nephrectomy (RN) whenever technically feasible. Nonetheless, indications, approaches, techniques for PN, and correct reporting of outcomes, are still a matter of great debate within the urology community. Concurrently, case-report series suggested that alternative strategies for the treatment of localized renal tumors (ablation tech... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2022
Locations: Institute of Urology, University of Southern California., Los Angeles, California
Conditions: Kidney Cancer
UCLA Breast Cancer Survivor Health Promotion Research Study
Recruiting
Pilot randomized controlled parallel group behavior change comparative effectiveness trial involves 30 breast cancer survivors interested in losing excess body fat. Both interventions include dietary + exercise prescriptions that hold promise for reducing the survivors' risk of cancer recurrence. Both interventions are consistent with the Dietary Guidelines for Americans but the Diabetes Prevention Program (DPP)-based approach focuses on weight loss through calorie restriction and increased phys... Read More
Gender:
Female
Ages:
Between 50 years and 75 years
Trial Updated:
04/01/2022
Locations: UCLA Center for Cancer Prevention & Control Research, Los Angeles, California
Conditions: Breast Cancer
Digitally-Captured Step Counts for Evaluating Performance Status in Advanced Cancer Patients
Recruiting
The purpose of this study is to examine the relationships between objectively measured physical activity and provider-assessed and patient-reported functional outcomes in patients with advanced cancer. Findings from this study will help us better understand how change in daily physical activity, as measured using the wearable activity monitor, is related to change in a patient's functional status and clinical condition.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/30/2022
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Cancer, Cancer, Metastatic, Neoplasms
Calibration of MR and PET-MR Imaging Protocols at RIC
Recruiting
This is a protocol to facilitate on-site calibration of the technical aspects of the Siemens Biograph mMR (molecular MR) Positron Emission Tomography-Magnetic Resonance (PET-MR) scanner and the 3T Siemens Vida MR scanner at the Cedars-Sinai Medical Center (CSMC) Biomedical Imaging Research Institute (BIRI) Research Imaging Core after scanner installation. The mMR is a FDA-approved standard clinical device (non-experimental) and will be used in accordance with clearance and approval from the FDA.... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2022
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Cancer, Coronary Artery Disease
Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies
Recruiting
This is a study of treatment with TBX-3400 in subjects with solid malignant tumors that are resistant or refractory to standard therapies. The subject's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity. The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response to the tumor.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2022
Locations: The Angeles Clinic and Research Institute, Los Angeles, California
Conditions: Cancer, Tumor, Solid, Refractory Cancer